Bacterial evolution and the cost of antibiotic resistance by Richard E. Lenski
Introduction
Antibiotic-resistant bacteria impose a substantial burden on
the human population. In addition to morbidity and mortality
caused by infections with resistant pathogens, society as a
whole must pay for the development of new antibiotics to
keep pace with continually evolving pathogens. It is clear,
therefore, that there is a cost associated with antibiotic
resistance from the perspective of human society. But is there
any cost associated with antibiotic resistance from the
perspective of a bacterium?
In an environment that contains an antibiotic, possession
of a corresponding resistance gene is clearly beneficial to a
bacterium. However, in the absence of antibiotic, resistant
genotypes may have lower growth rates than their sensitive
counterparts. Mutations that confer resistance do so by
disrupting some normal physiological process in the cell,
thereby causing detrimental side-effects. In the case of plasmid-
encoded resistance functions, bacteria must synthesize additional
nucleic acids and proteins; this synthesis imposes an energetic
burden [7] and the products that are synthesized may interfere
with the cell’s physiology [12]. Resistant bacteria may therefore
be inferior competitors to sensitive genotypes in the absence
of antibiotics. If so, then a strategy for containing the spread
of resistance would be to suspend the use of a particular
antibiotic until resistant genotypes had declined to low
frequency. (See [3] for a detailed analysis of this and related
strategies.)
The efficacy of this strategy depends, in part, on the cost
of antibiotic resistance to the bacteria. Assuming that some
sensitive bacteria survive antibiotic treatment (or colonize after
the treatment has ended), the amount of time necessary to reduce
the abundance of resistant bacteria to a specified low level is
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Bacterial evolution and the cost 
of antibiotic resistance
Summary Bacteria clearly benefit from the possession of an antibiotic resistance
gene when the corresponding antibiotic is present. But do resistant bacteria suffer
a cost of resistance (i.e., a reduction in fitness) when the antibiotic is absent? If
so, then one strategy to control the spread of resistance would be to suspend the
use of a particular antibiotic until resistant genotypes declined to low frequency.
Numerous studies have indeed shown that resistant genotypes are less fit than
their sensitive counterparts in the absence of antibiotic, indicating a cost of
resistance. But there is an important caveat: these studies have put resistance
genes into naive bacteria, which have no evolutionary history of association with
the resistance genes. An important question, therefore, is whether bacteria can
overcome the cost of resistance by evolving adaptations that counteract the harmful
side-effects of resistance genes. In fact, several experiments (in vitro and in vivo)
show that the cost of antibiotic resistance can be substantially diminished, even
eliminated, by evolutionary changes in bacteria over rather short periods of time.
As a consequence, it becomes increasingly difficult to eliminate resistant genotypes
simply by suspending the use of antibiotics.
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inversely proportional to the cost of resistance. For example,
it would take ten times as long to eliminate a population of
resistant bacteria when the cost of resistance is only 1% as
compared to when the cost of resistance is 10% [10]. Thus, the
efficacy of controlling the spread of antibiotic resistance by
suspending the usage of an antibiotic is critically dependent
on the relative fitness of resistant and sensitive genotypes in
the absence of antibiotic.
In the following sections, I review several experiments that
have measured the costs of antibiotic resistance from the
perspective of bacteria. The major findings are two-fold. On
the one hand, resistant bacteria are often inferior competitors
to their sensitive counterparts in the absence of antibiotic. On
the other hand, the costs of antibiotic resistance can evolve,
and they tend to be reduced over time by natural selection.
Unfortunately, this trend implies that it will become more and
more difficult over time to control the spread of resistant strains. 
Results and Discussion
Consensus findings indicate a cost to resistance Many studies
have shown that resistant genotypes are less fit than their
sensitive progenitors when the two compete in an antibiotic-
free medium. Some of these studies have demonstrated costs
associated with carriage of plasmids and expression of plasmid-
encoded resistance functions (e.g., [23]), whereas others have
demonstrated side-effects of resistance mutations that impair
growth (e.g., [8]). 
In some other studies, there was no discernible cost to
antibiotic resistance. Perhaps these results reflect a real absence
of cost, or perhaps they simply indicate that the cost was too
small to be seen given the experimental resolution. For example,
Nguyen et al. [16] observed a large cost due to constitutive
expression of plasmid-encoded tetracycline resistance in
Escherichia coli, but they could not measure any significant
cost for inducible resistance beyond the small cost of the
plasmid vector itself. Evidently, repression of a resistance gene
can be quite effective in avoiding the cost of resistance in an
antibiotic-free environment. 
I know of only one study in which a resistance function was
shown to confer an immediate (see below) selective advantage
in the absence of antibiotic. Blot et al. [2] showed that a Tn5-
encoded bleomycin-resistance gene enhanced the survival of
E. coli during prolonged starvation, even though no antibiotic
was present. Bleomycin causes damage to DNA, and such
damage may also occur during prolonged starvation. The gene
product responsible for bleomycin resistance is thought to play
some role in DNA repair, which may explain its beneficial
effect during starvation. 
But there is a caveat The preceding evidence indicates that
resistant bacteria are often at a competitive disadvantage relative
to their sensitive counterparts when there is no antibiotic present
in the environment. However, there is an important qualification
to this conclusion: These studies have been performed by putting
an antibiotic-resistance gene (either a plasmid-encoded function
or a chromosomal mutation) into a “naive” bacterium, one which
has no evolutionary history of association with that resistance
gene. An important question, therefore, is whether the cost of
resistance can be reduced or even eliminated by allowing the
bacterium to adapt to the resistance gene. I will now review
several experimental studies that have addressed this issue.
Evolutionary reductions in the cost of plasmid-encoded
antibiotic resistance Plasmid pACYC184 encodes resistance
to two antibiotics, tetracycline and chloramphenicol. Bouma
and Lenski [4] transformed a laboratory strain of E. coli with
pACYC184, and they showed that the plasmid-bearing construct
was competitively inferior relative to its plasmid-free counterpart
in a minimal medium without antibiotic (Fig. 1A). The bacterial
strain that they used had no history of association with
pACYC184, and so they sought to determine if the cost of
plasmid carriage could be reduced by evolutionary changes in
either the host or the plasmid. To that end, Bouma and Lenski
propagated the plasmid-host association for 500 generations
(75 days) in the same medium, except supplemented with
chloramphenicol. (The supplemental antibiotic prevented
spontaneous plasmid-free segregants from out-competing the
plasmid-bearing cells, which would have defeated the purpose
of the experiment.)
After 500 generations, Bouma and Lenski [4] isolated a
spontaneous plasmid-free segregant of the evolved bacterial
host. They then transformed each of the ancestral and evolved
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Fig. 1 Effects of pACYC184 on the fitness of ancestral and evolved Escherichia
coli hosts, in the absence of any antibiotic (summary of data from reference
[13]). B0 denotes the ancestral genotype, and B500 is a genotype that evolved
with pACYC184 for 500 generations. (A) Fitness of B0/pACYC184 versus its
plasmid-free counterpart, B0. (B) Fitness of B500/pACYC184 versus its plasmid-
free counterpart, B500. The values shown in (A) and (B) are the means of 30
replicate competition experiments. The costs and benefits of plasmid carriage
for the ancestral and evolved genotypes, respectively, are both statistically
significant
hosts with both the ancestral and evolved plasmids, giving four
genotypes: B0/P0, B0/P500, B500/P0, and B500/P500, where B and
P denote the bacteria and plasmid, respectively, and subscripts
0 and 500 indicate the ancestral (naive) and evolved forms,
respectively. Each of these genotypes was placed in competition
with a genetically marked variant of B0/P0 in the same medium
used during the 500 generations of experimental evolution.
These competition experiments indicated that genetic adaptation
had occurred in the bacterial chromosome, but not in the
plasmid. That is, B500 was competitively superior to B0, and its
advantage was unaffected by the plasmid’s evolutionary status.
These data demonstrated that the bacteria had adapted
evolutionarily, but they did not show whether the bacteria had
adapted to the plasmid, to the culture medium, or to some
combination of the two.
To determine whether the bacteria had adapted to the
plasmid, Bouma and Lenski [4] performed competition
experiments in antibiotic-free medium between the evolved
bacteria with and without the ancestral plasmid (i.e., B500/P0
versus B500). If the bacteria had adapted specifically to the
plasmid, then the cost of carriage should be lower in the evolved
bacteria than in the ancestor. To their surprise, Bouma and
Lenski found that the evolved plasmid-bearing bacteria had a
competitive advantage relative to the evolved plasmid-free
bacteria even in the absence of antibiotic (Fig. 1B). Thus, not
only was the cost of plasmid carriage eliminated, but the plasmid
actually benefited the bacteria that had evolved with the plasmid
present.
Lenski et al. [13] sought to identify what aspect of the
plasmid was beneficial to the evolved bacteria, but not to its
naive ancestor. They constructed a series of plasmids in which
they deleted either the chloramphenicol or tetracycline
resistance functions from pACYC184. Resistance to
chloramphenicol occurs by the enzymatic acetylation of the
antibiotic, which renders it inactive. Resistance to tetracycline
involves active efflux of the antibiotic using a trans-membrane
protein. They showed that expression of chloramphenicol
resistance imposed a significant cost for both the naive and
evolved host bacteria. However, expression of the tetracycline
resistance function was actually beneficial to the evolved
bacteria (but not to the naive ancestor) in the absence of
antibiotic. That is, an evolved host which carries a plasmid
that expresses tetracycline resistance is competitively superior
to its plasmid-free counterpart, whereas an evolved host which
carries a plasmid that does not express tetracycline resistance
is less fit than its plasmid-free counterpart (Table 1). 
Although the physiological basis of this effect is not yet
fully understood, this study shows clearly that the cost of
plasmid-encoded antibiotic resistance can be reduced or even
eliminated by natural selection. When pACYC184 was
introduced into the naive bacterium, it was lost in the absence
of antibiotic as spontaneous plasmid-free segregants
competitively excluded the plasmid-bearing cells. But as a
consequence of the evolutionary adaptation of the bacteria to
the plasmid, plasmid-free segregants no longer have a
competitive advantage and the plasmid-encoded antibiotic
resistance is stably maintained.
In a conceptually similar study, Modi and Adams [15]
examined the coevolution of E. coli and a derivative of
plasmid pBR322 that encodes resistance to ampicillin and
tetracycline. After about 800 generations, they found that
the cost of plasmid carriage to the bacterial host had been
significantly reduced, although it was not entirely eliminated
in this case. They also showed that genetic changes in both
the bacterial and plasmid genomes contributed to the reduced
cost of plasmid carriage. As with the previous study, Modi
and Adams’ results indicate that it can become more difficult
to eliminate resistance after bacteria and plasmids have had
a history of association.
Turner et al [22] recently examined a somewhat different,
but related, question: How does the cost of plasmid carriage
depend on the plasmid’s transmissibility? Starting with a
conjugative plasmid isolated from nature, they derived ten
plasmids during a 500-generation experiment. Five of these
plasmids evolved higher rates of conjugative transmission than
the ancestral plasmid, while five others evolved lower rates
(including two that became unable to conjugate). The plasmids
that had evolved higher conjugation rates became more costly
to the bacteria than was the ancestral plasmid, whereas those
that evolved lower conjugation rates were less costly. Evidently,
the cost of plasmid carriage may increase or decrease, depending
on the selective challenges that confront—and genetic solutions
available to—a population of plasmids. Thus, a plasmid should
tend to evolve a lower cost of carriage, all else equal, but
selection for increased expression of a plasmid-encoded function
(transmissibility, resistance, etc.) may sometimes oppose this
tendency. 
Evolutionary reductions in the cost of chromosomal
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Table 1 Expression of tetracycline resistance is beneficial to an Escherichia
coli host that evolved with plasmid pACYC184 (summary of data from
[13])
Plasmid Cm Tc Naive host Evolved host
pACYC184 R R – +
pMP10 S R 0 ++
pMP11 S R 0 ++
pSCS1 R S – –
pSCS13 R S – –
Abbreviations: Cm, chloramphenicol; Tc, tetracycline; R, resistant; S, sensitive.
Plasmids pMP10 and pMP11 have deletions in the gene for chloramphenicol
resistance. Plasmids pSCS1 and pSCS13 have deletions in the gene for
tetracycline resistance. The last two columns indicate the effect of plasmid
carriage on the fitness of naive and evolved bacterial hosts, in the absence 
of antibiotic. –, significant cost. 0, no significant effect. +, significant benefit.
++, significantly larger benefit.
mutations that confer antibiotic resistance The finding that
the cost of antibiotic resistance can be reduced is not restricted
to plasmid-encoded resistance. Schrag and Perrot [18]
examined mutations in the rpsL gene of E. coli that confer
resistance to streptomycin. In the absence of antibiotic, cells
that carry these mutations are handicapped in competition with
otherwise isogenic cells sensitive to streptomycin. The
streptomycin resistant mutants have altered ribosomes and a
lower rate of peptide-chain elongation, which may account
for the cost of resistance. Schrag and Perrot also sought to
determine if the cost of antibiotic resistance could be reduced
by allowing the bacteria to evolve. After less than 200
generations of evolution in the absence of antibiotic, they found
that the cost of resistance was substantially reduced. This cost-
reduction was achieved without any significant change in the
level of streptomycin resistance. Schrag and Perrot
demonstrated that cost-reduction was achieved by secondary
mutations outside the rpsL gene, and that these secondary
mutations restored the rate of peptide-chain elongation to a
level close to that of the sensitive progenitor (Fig. 2). More
recently, Schrag et al. [19] also showed that, after these
secondary mutations had achieved fixation in the population,
sensitive genotypes were at a competitive disadvantage relative
to resistant genotypes, even in the absence of streptomycin.
Thus, there is no selective advantage to sensitive revertants
once the secondary mutations that compensate for resistance
have spread throughout the population (although sensitive
bacteria without compensatory mutations are still the most fit
type in this system and might invade from other populations).
Evidently, evolving populations of bacteria can often
compensate for the deleterious side-effects of resistance genes,
including mutations as well as plasmid-encoded functions,
and this compensation makes it more difficult or even
impossible to restore antibiotic sensitivity by temporarily
suspending the use of an antibiotic. 
Cohan et al. [5] examined the cost of resistance to rifampicin
in Bacillus subtilis. Mutations that confer resistance to
rifampicin occur in the rpoB gene, which encodes the β subunit
of the RNA polymerase, and these mutations tend to reduce
the competitive fitness of the bacteria in the absence of
antibiotic. However, Cohan et al. showed that the magnitude
of this cost was variable depending on the specific mutation to
rifampicin resistance as well as the particular strain of B. subtilis
into which a mutation was transformed. (The cost of resistance
did not correlate with the level of rifampicin resistance, which
was high for all combinations of resistance alleles and genetic
backgrounds.) This study therefore implies two mechanisms
by which the cost of resistance can be ameliorated. First,
selection among resistance alleles will favor those which impose
the lowest costs. Second, selection among genetic backgrounds
will favor those which are subject to the lowest costs. As a
consequence of selection, the cost of resistance to rifampicin
should become progressively reduced over time, as only the
most fit combinations of resistance alleles and genetic
backgrounds will prevail in competition.
Do similar phenomena occur in nature? The experiments
reviewed above, showing the cost of resistance and its
evolutionary reduction, were all performed in the laboratory
and in vitro. Björkman et al. [1] recently extended these
findings to an in vivo system. They demonstrated that mutants
of Salmonella typhimurium resistant to streptomycin,
rifampicin, or nalidixic acid were usually avirulent in mice,
indicating that this pathogen suffers a profound cost of
antibiotic resistance. But as was the case in vitro, the bacteria
evolved compensatory mutations that reduced the cost of
resistance and restored their virulence, even while they kept
their resistance to the antibiotics. 
And there is every reason to believe that similar
phenomena occur in nature. For example, Neisseria
gonorrhoeae was for many years universally susceptible to
ampicillin. In 1976, resistant strains were first detected that
had a plasmid-encoded β-lactamase, probably derived from
an enteric bacterium. According to Roberts et al. [17], the
resistance plasmids were initially very unstable, but within
a few months they had become much more stable. A plausible
explanation for this increased stability is an evolutionary
reduction in the cost of antibiotic resistance, because plasmid
instability is strongly affected by even small differences in
the growth rate of plasmid-bearing cells and plasmid-free
segregants [6, 11]. If some other antibiotic had been used to
treat gonorrhea when resistance to ampicillin was first
detected, and while the plasmid was still unstable, then
resistance might have disappeared from the population;
ampicillin could then have been used for many more years.
But once the plasmid was stabilized, it became difficult or
impossible to restore sensitivity. Evolutionary reductions in
the cost of resistance have also been proposed to explain the
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Fig. 2 Rates of peptide chain elongation in Escherichia coli  genotypes sensitive
and resistant to streptomycin (summary of data from reference [18]). (A) Ancestral
sensitive genotype. (B) Average ot two resistant genotypes. (C) Average of four
resistant genotypes after 180 generations of evolutionary cost-reduction. The
difference between (A) and (B) is statistically significant, whereas the difference
between (A) and (C) is not
surprising tenacity of resistance to tetracycline and
streptomycin [9, 20, 21]. The role of cost-reduction in
extending the persistence of antibiotic-resistance genes in
nature deserves further careful study.
Evolutionary cost-reduction is not restricted to antibiotic
resistance Proliferation of antibiotic-resistant bacteria
provides a dramatic example of evolution because of its
rapidity as well as its medical importance. However, the
evolution of resistance, the costs associated with resistance
functions, and the subsequent reduction of costs occur in
other circumstances as well. McKenzie et al. [14] describe
a compelling example of all these phenomena in an insect
pest. For about ten years, the insecticide diazinon was
successfully used to control the Australian sheep blowfly,
Lucilia cuprina. A mutation that conferred resistance
eventually appeared and diazinon-resistant flies subsequently
became widespread. At first, resistant flies developed more
slowly and had reduced survival relative to their sensitive
progenitors in the absence of insecticide, indicating a cost
of resistance. After a few more years of continued usage of
diazinon, however, a second mutation appeared in the fly
population that eliminated the cost of resistance. Diazinon-
resistant flies that had this second mutation were as fit as
sensitive flies, even in the absence of diazinon. The
opportunity to control the spread of resistance by temporarily
suspending the use of diazinon was lost.
In summary, evolutionary cost-reduction is a simple and
general manifestation of the tendency for organisms to
undergo genetic adaptation by natural selection. Just as
organisms may adapt to overcome adverse aspects of their
external environment (e.g., by becoming resistant to
antibiotics), so too may they adapt to overcome adverse
aspects of their internal physiology (e.g., by reducing any
harmful side-effects of resistance).
Conclusions
(i) The sensitivity of bacterial pathogens to antibiotics can be
viewed as a natural resource, one which has tremendous value
to the human population. Unfortunately, much of this resource
has already been depleted in the last half-century, as a
consequence of the evolution of pathogens that are resistant to
antibiotics. 
(ii) In principle, antibiotic sensitivity is a renewable resource.
If there is a cost of resistance to bacteria, then sensitivity may
be renewed by temporarily suspending the use of an antibiotic
to which resistance has emerged, thereby allowing sensitive
genotypes to competitively displace their resistant counterparts. 
(iii) However, after evolving resistance to antibiotics, bacteria
may then adapt to the deleterious side-effects and other costs
of resistance genes. Therefore, with continued use of an
antibiotic after the emergence of resistant genotypes, it may
become increasingly difficult to renew sensitivity.
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